Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Conformational properties of HIV-1 gp120/V3 immunogenic domains.

Galanakis PA, Spyroulias GA, Rizos A, Samolis P, Krambovitis E.

Curr Med Chem. 2005;12(13):1551-68. Review.

PMID:
15974987
2.
3.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

4.

HIV-1 infection and chemokine receptor modulation.

Ruibal-Ares BH, Belmonte L, Baré PC, Parodi CM, Massud I, de Bracco MM.

Curr HIV Res. 2004 Jan;2(1):39-50. Review.

PMID:
15053339
5.

NMR studies of V3 peptide complexes with antibodies suggest a mechanism for HIV-1 co-receptor selectivity.

Sharon M, Rosen O, Anglister J.

Curr Opin Drug Discov Devel. 2005 Sep;8(5):601-12. Review.

PMID:
16159022
6.

Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity.

Xiao X, Phogat S, Shu Y, Phogat A, Chow YH, Wei OL, Goldstein H, Broder CC, Dimitrov DS.

Vaccine. 2003 Oct 1;21(27-30):4275-84.

PMID:
14505910
8.

Synthetic peptides for study of human immunodeficiency virus infection.

Dettin M, Scarinci C, Pasquato A, Di Bello C.

Appl Biochem Biotechnol. 2002 Jul-Dec;102-103(1-6):41-7. Review.

PMID:
12396109
9.

Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.

Dimonte S, Babakir-Mina M, Mercurio F, Di Pinto D, Ceccherini-Silberstein F, Svicher V, Perno CF.

Virus Res. 2012 Sep;168(1-2):73-83. doi: 10.1016/j.virusres.2012.06.019. Epub 2012 Jun 23.

PMID:
22732432
10.

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Rizzuto CD, Wyatt R, Hernández-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J.

Science. 1998 Jun 19;280(5371):1949-53.

11.

Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans.

van Montfort T, Thomas AA, Pollakis G, Paxton WA.

J Virol. 2008 Aug;82(16):7886-96. doi: 10.1128/JVI.00245-08. Epub 2008 Jun 4.

12.
13.

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.

Seibert C, Sakmar TP.

Curr Pharm Des. 2004;10(17):2041-62. Review.

PMID:
15279544
14.

Electrostatic modeling of peptides derived from the V3-loop of HIV-1 gp120: implications of the interaction with chemokine receptor CCR5.

Morikis D, Rizos AK, Spandidos DA, Krambovitis E.

Int J Mol Med. 2007 Mar;19(3):343-51.

PMID:
17273779
15.

Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.

Rosen O, Chill J, Sharon M, Kessler N, Mester B, Zolla-Pazner S, Anglister J.

Biochemistry. 2005 May 17;44(19):7250-8.

PMID:
15882063
16.

Inhibitors of the entry of HIV into host cells.

Meanwell NA, Kadow JF.

Curr Opin Drug Discov Devel. 2003 Jul;6(4):451-61. Review.

PMID:
12951808
17.

An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.

Taylor BM, Foulke JS, Flinko R, Heredia A, DeVico A, Reitz M.

J Virol. 2008 Jun;82(11):5460-71. doi: 10.1128/JVI.01049-07. Epub 2008 Mar 19.

18.

Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.

Huang L, Zhang L, Chen CH.

Curr Pharm Des. 2003;9(18):1453-62. Review.

PMID:
12769725
19.

Importance of V3 loop flexibility and net charge in the context of co-receptor recognition. A molecular dynamics study on HIV gp120.

Chandramouli B, Chillemi G, Abbate I, Capobianchi MR, Rozera G, Desideri A.

J Biomol Struct Dyn. 2012;29(5):879-91.

PMID:
22292949

Supplemental Content

Support Center